Clinical Trial Update: Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 dose-escalation trial of ponatinib, a FLT3 inhibitor, with and without 5-azacytidine in FLT3-mutated acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• 5-Azacytidine (5-azacytidine)
• Ponatinib (ponatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, FLT3-Mutated Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN